Evidence map›Paper›PMID 32749152›Full record

ReviewCell transplantation

A Review of Advances in Hematopoietic Stem Cell Mobilization and the Potential Role of Notch2 Blockade.

Marwah Albakri, Hammad Tashkandi, Lan Zhou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Current Views on the Roles ofBiomolecules · 2021
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Marwah AlbakriDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Hammad TashkandiDepartment of Pathology, University of Pittsburgh Medical Center, PA, USA.
Lan ZhouDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0003-1291-534X
Case Western Reserve University · USUniversity of Pittsburgh Medical Center · US

Funding

Targeting Notch2 in Hematopoietic Cell Therapy.R01HL103827 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZHOU, LAN · 2012 to 2022
$4.3M
Hes1-loss promotes dysregulation of epithelial homeostasis and inflammation in a serrated adenocarcinoma modelR01CA222064 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZHOU, LAN · 2018 to 2022
$2.0M
Role of CRABP-II in pancreatic cancer metastasisR03CA201738 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI YU, SHUILIANG, ZHOU, LAN · 2017 to 2018
$160k
NCI NIH HHS R01 CA222064NCI NIH HHS R03 CA201738NHLBI NIH HHS R01 HL103827
6 · The paper itself

Abstract

Hematopoietic stem cell (HSC) transplantation can be a potential cure for hematological malignancies and some nonhematologic diseases. Hematopoietic stem and progenitor cells (HSPCs) collected from peripheral blood after mobilization are the primary source to provide HSC transplantation. In most of the cases, mobilization by the cytokine granulocyte colony-stimulating factor with chemotherapy, and in some settings, with the CXC chemokine receptor type 4 antagonist plerixafor, can achieve high yield of hematopoietic progenitor cells (HPCs). However, adequate mobilization is not always successful in a significant portion of donors. Research is going on to find new agents or strategies to increase HSC mobilization. Here, we briefly review the history of HSC transplantation, current mobilization regimens, some of the novel agents that are under investigation for clinical practice, and our recent findings from animal studies regarding Notch and ligand interaction as potential targets for HSPC mobilization.

Indexed as

Hematopoietic Stem Cell MobilizationReceptor, Notch2NOTCH2 protein, humanReceptor, Notch2G-CSFhematopoietic stem cell transplantationmobilizationNotch2 blockadeplerixafor

Identifiers

PMID32749152
PMCPMC7563033
OpenAlexW3047372050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.